INCB024360 analogues are primarily explored for their potential in cancer therapy, particularly in targeting the immune system to enhance anti-tumor responses. These compounds are designed to inhibit specific enzymes, such as indoleamine 2,3-dioxygenase (IDO1), which play a role in immune suppression within the tumor microenvironment. By blocking these enzymes, the analogues help to reactivate the immune system's ability to recognize and attack cancer cells. This makes them promising candidates for combination therapies with other immunotherapies or conventional treatments like chemotherapy. Research is ongoing to evaluate their efficacy and safety in clinical trials, with a focus on improving outcomes for patients with various types of cancer.